Review
Biology
Song-Yang Wu, Hai Wang, Zhi-Ming Shao, Yi-Zhou Jiang
Summary: Triple-negative breast cancer is the most aggressive cluster among all breast cancers, and advances in cancer genomics allow identification of different subtypes for predicting treatment responses and selecting therapeutic targets.
SCIENCE CHINA-LIFE SCIENCES
(2021)
Review
Oncology
Fokhrul Hossain, Samarpan Majumder, Justin David, Lucio Miele
Summary: The implementation of precision medicine is set to revolutionize cancer treatment paradigms, offering hope for patients with triple-negative breast cancer. However, challenges remain as oncologists navigate the complexities of tumor heterogeneity and evolution in designing personalized treatment plans.
Article
Chemistry, Medicinal
Cheng Wang, Xinye Chen, Xingchen Liu, Dehua Lu, Shang Li, Lailiang Qu, Fucheng Yin, Heng Luo, Yonglei Zhang, Zhongwen Luo, Ningjie Cui, Lingyi Kong, Xiaobing Wang
Summary: EZH2 is often overexpressed in TNBC and other tumors, affecting tumor development and prognosis. The designed PROTACs molecule U3i precision targets EZH2 and shows good inhibitory effects on TNBC cells, inducing apoptosis without causing much damage to normal cells. U3i is a potential anticancer molecule for TNBC treatment.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Alessia Vignoli, Emanuela Risi, Amelia McCartney, Ilenia Migliaccio, Erica Moretti, Luca Malorni, Claudio Luchinat, Laura Biganzoli, Leonardo Tenori
Summary: Precision oncology focuses on selecting the optimal therapy for individual patients with breast cancer, who need appropriate stratification for maximizing survival and quality of life. Gene-expression tools assist in estimating risk and benefit from chemotherapy, while NMR metabolomics has shown promising results in BC research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Karen Pinilla, Lynsey M. Drewett, Rebecca Lucey, Jean E. Abraham
Summary: Personalised approaches to the management of triple-negative breast cancers (TNBC) are important due to the disease's heterogeneity and distinct molecular alterations. Historically, cytotoxic chemotherapy has been the mainstay of treatment for TNBC, but it is associated with off-target tissue toxicity and drug resistance. Neoadjuvant chemotherapy is commonly used and provides valuable prognostic information. Platinum chemotherapy, DNA damage response (DDR) inhibitors, immune checkpoint inhibitors, inhibitors of the PI3K-AKT-mTOR, and androgen receptor (AR) pathways are increasingly studied therapies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shan-Ju Yeh, Bo-Jie Hsu, Bor-Sen Chen
Summary: Triple-negative breast cancer (TNBC) is a subtype with poor prognosis, and understanding the molecular mechanisms is challenging due to cascade signaling pathways and genetic regulations. A systematic design using systems biology approaches identified potential multi-molecule drugs for both TNBC and non-TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Nutrition & Dietetics
Michael F. Coleman, Ciara H. O'Flanagan, Alexander J. Pfeil, Xuewen Chen, Jane B. Pearce, Susan Sumner, Sergey A. Krupenko, Stephen D. Hursting
Summary: The study indicates that the sensitivity of TNBC to folate restriction is primarily driven by high innate levels of mitochondrial dysfunction, which can increase dependence on one-carbon metabolism. Folate deprivation or antifolate therapy may represent a novel precision medicine strategy for TNBC with metabolic inflexibility due to elevated levels of mitochondrial dysfunction.
Review
Pharmacology & Pharmacy
Yifeng Cao, Chuyang Chen, Yi Tao, Weifeng Lin, Ping Wang
Summary: Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, leading to increased mortality of patients due to accelerated aggressiveness and terrible metastasis. Hindered by the negative expression of certain receptors, targeted therapy has been challenging, but the higher immune response in TNBC compared to other breast cancer types makes it suitable for immunotherapy.
Article
Pharmacology & Pharmacy
Thien-Nga Chamaraux-Tran, Marie Muller, Julien Pottecher, Pierre A. Diemunsch, Catherine Tomasetto, Izzie-Jacques Namer, Nassim Dali-Youcef
Summary: Metabolomics and onco-anesthesia are emerging research fields in oncology. This study assessed the impact of lidocaine (LIDO) on the metabolomic fingerprint of breast cancer cells. Results showed that LIDO modulates cell metabolites levels and downregulates several pathways, suggesting its potential antitumor properties.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Xin Xu, Xiangyan Ruan, Ying Zhang, Guiju Cai, Rui Ju, Yu Yang, Jiaojiao Cheng, Muqing Gu
Summary: This study discovered a correlation between high expression of PGRMC1 in TNBC and poor prognosis, possibly through a mitochondria-associated pathway. Lower levels of PGRMC1 expression were associated with better survival rates.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Zainab Al-Taie, Mark Hannink, Jonathan Mitchem, Christos Papageorgiou, Chi-Ren Shyu
Summary: Breast cancer (BC) is a leading cause of death for female cancer patients, with triple-negative breast cancer (TNBC) having the lowest survival rate. This study utilized a novel patient stratification and drug repositioning method to identify subgroups of BC patients with common genetic profiles and responses to drugs. By applying this method to TNBC, five druggable subgroups were identified, with potential drugs selected based on targeted mechanisms specific to each subgroup.
Review
Biochemistry & Molecular Biology
Eva Kudelova, Marek Smolar, Veronika Holubekova, Andrea Hornakova, Dana Dvorska, Vincent Lucansky, Lenka Koklesova, Erik Kudela, Peter Kubatka
Summary: The heterogeneity of triple-negative breast cancer is well known at clinical, histopathological, and molecular levels. Genomic instability, greater mutation rates, and altered immune response-related genes are associated with this breast cancer type. Long non-coding RNAs also play a crucial role in shaping the tumor microenvironment and mediating tumor immune evasion. Developing targeted cancer treatments and personalized medicine can improve outcomes for patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Thomas J. Velenosi, Kristopher W. Krausz, Keisuke Hamada, Tiffany H. Dorsey, Stefan Ambs, Shogo Takahashi, Frank J. Gonzalez
Summary: This study identifies urine diacetylspermine as a non-invasive biomarker of doxorubicin effectiveness in triple-negative breast cancer (TNBC) patients, through pharmacometabolomics study.
NPJ PRECISION ONCOLOGY
(2022)
Letter
Medicine, General & Internal
Shuvadeep Ganguly, Ajay Gogia
Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Chengheng Liao, Cherise Ryan Glodowski, Cheng Fan, Juan Liu, Kevin R. Mott, Akash Kaushik, Hieu Vu, Jason W. Locasale, Samuel K. McBrayer, Ralph J. DeBerardinis, Charles M. Perou, Qing Zhang
Summary: Metabolic dysregulation in breast cancer was characterized and divided into two major metabolic groups. Genes strongly correlated with metabolic dysregulation and predicted patient prognosis were identified. Targeting metabolic dysregulation led to effective therapeutic outcomes. This study is of great significance in guiding therapeutic strategies for breast cancer subsets.
Article
Oncology
Yun-Song Yang, Yi-Xing Ren, Cheng-Lin Liu, Shuang Hao, Xiao-En Xu, Xi Jin, Yi-Zhou Jiang, Zhi-Ming Shao
Summary: Using RNA-sequencing data, researchers developed a prognostic signature with 7 mRNA markers that accurately predicts the recurrence risks of early-stage triple-negative breast cancer (TNBC) patients.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Alexandre de Nonneville, Francois Bertucci, Eric Lambaudie, Gilles Houvenaeghel, Renaud Sabatier, Anthony Goncalves, Patrice Viens
Summary: This study evaluated the publication rate and associated patterns among medical oncology residents in France, and identified key factors influencing publication. The results showed that starting the thesis project early improves the publication rate.
BULLETIN DU CANCER
(2022)
Article
Biochemistry & Molecular Biology
Victoire Gouirand, Tristan Gicquel, Evan C. Lien, Emilie Jaune-Pons, Quentin Da Costa, Pascal Finetti, Elodie Metay, Camille Duluc, Jared R. Mayers, Stephane Audebert, Luc Camoin, Laurence Borge, Marion Rubis, Julie Leca, Jeremy Nigri, Francois Bertucci, Nelson Dusetti, Juan Lucio Iovanna, Richard Tomasini, Ghislain Bidaut, Fabienne Guillaumond, Matthew G. Vander Heiden, Sophie Vasseur
Summary: Pancreatic ductal adenocarcinoma cells can activate ketone body metabolism using beta-hydroxybutyrate (beta OHB) as a fuel, which promotes PDA growth and progression. HMGCL, involved in ketogenesis, is found to be deregulated in PDA and its depletion impairs PDA migration and invasiveness. Disrupting HMGCL decreases PDA tumor growth, while beta OHB stimulates metastatic dissemination to the liver.
Article
Oncology
Justine Gantzer, Guillaume Davidson, Bujamin Vokshi, Noelle Weingertner, Antoine Bougouin, Marco Moreira, Veronique Lindner, Guillaume Lacroix, Celine Mascaux, Marie-Pierre Chenard, Francois Bertucci, Irwin Davidson, Jean-Emmanuel Kurtz, Catherine Sautes-Fridman, Wolf H. Fridman, Gabriel G. Malouf
Summary: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) mainly have an immune desert tumor microenvironment (TME) and limited efficacy to immune checkpoint inhibitors (ICI). The TME of SMARCA4-driven tumors varies according to the cell of origin.
Article
Oncology
David Jeremie Birnbaum, Maelle Picard, Quentin Da Costa, Thomas Delayre, Pascal Finetti, Olivier Cabaud, Emilie Agavnian, Bernadette De Rauglaudre, Emilie Denicolai, Francois Bertucci, Emilie Mamessier
Summary: Hepatocellular carcinoma (HCC) is a common and deadly cancer, and new treatments are needed. Immune checkpoint inhibitors (ICIs) have shown promise for HCC. By analyzing a large transcriptomic database, we found that the TIGIT/DNAM-1 axis, particularly the PVRIG molecule, could be a potential therapeutic option for HCC.
Article
Oncology
Wen -Ting Peng, Xi Jin, Xiao-En Xu, Yun-Song Yang, Ding Ma, Zhi-Ming Shao, Yi-Zhou Jiang
Summary: This study identifies ACAA1 as a potential therapeutic target for TNBC, specifically in the LAR subtype. Inhibition of ACAA1 can suppress TNBC proliferation and enhance the response to abemaciclib. The combination of trimetazidine and abemaciclib shows promise in treating ACAA1-high TNBCs.
Article
Cell Biology
Gatha Thacker, Samantha Henry, Ajeya Nandi, Rahul Debnath, Snahlata Singh, Anupma Nayak, Barbara Susnik, Melinda M. Boone, Qing Zhang, Susan B. Kesmodel, Sanjeev Gumber, Gokul M. Das, Taku Kambayashi, Camila O. Dos Santos, Rumela Chakrabarti
Summary: Using single-cell RNA sequencing and functional analysis, a unique population of Socs3(high)CD11b(-)CD27(-) immature NK cells was identified in triple-negative breast cancer (TNBC) samples. These NK cells activated cancer stem cells through Wnt signaling, promoting tumor progression. Depletion of NK cells or inhibition of Wnt ligand secretion from NK cells reduced tumor progression. Furthermore, depletion of NK cells or inhibition of their function enhanced the response to anti-PD-L1 antibody or chemotherapy in TNBC mice.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Review
Oncology
Alexandre Bertucci, Francois Bertucci, Anthony Goncalves
Summary: Breast cancer is a major cause of death worldwide and there is a need for improved therapies. The PI3K pathway is commonly altered in breast cancer subtypes and is an attractive therapeutic target. Pan-PI3K inhibitors have paved the way for selective PI3K inhibitor development, although their clinical activity is modest with high toxicity. This overview discusses the past, present, and potential future of PI3K inhibitors for breast cancer.
Article
Biochemical Research Methods
Wentong Fang, Chengheng Liao, Qing Zhang
Summary: Chromatin immunoprecipitation (ChIP) assay is commonly used to study the interaction between DNA and DNA-binding proteins. The success of a ChIP assay relies heavily on the quality of the primary antibody. In cases where specific antibodies are unavailable or have low binding affinity, a tailored protocol involving the expression of an exogenous epitope-tagged protein can be used for robust and reproducible chromatin binding.
Article
Computer Science, Hardware & Architecture
Kangzhe He, Qiuzhuang Sun, Min Xie, Way Kuo
Summary: This article proposes a sequential ADT planning model that considers sensor degradation to improve the performance of the test plan.
IEEE TRANSACTIONS ON RELIABILITY
(2023)
Article
Engineering, Manufacturing
Qiuzhuang Sun, Piao Chen, Xin Wang, Zhi-Sheng Ye
Summary: This study focuses on the robust production and maintenance control for a production system subject to degradation. A periodic maintenance scheme and dynamic adjustment of the production rate are considered to minimize maintenance cost in the worst case. Real-time condition-based control of the production rate is proposed as an improvement.
PRODUCTION AND OPERATIONS MANAGEMENT
(2023)
Article
Oncology
Olivier Tredan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle de la Fouchardiere, Francois Bertucci, Anthony Goncalves, Carlos Gomez-Roca, Benoit You, Valery Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Severine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenael Garin, Jean-Yves Blay, David Perol
Summary: Using a randomized discontinuation design, sorafenib was tested on patients with advanced/metastatic solid tumors harboring sorafenib-targeted genes. Continuing sorafenib when stable disease is achieved improves progression-free rate compared to interruption. Sorafenib has tumor-agnostic efficacy in patients with tumors harboring genomic alterations in PDGFRA/B, VEGF-Rs, Flt-3, KIT, FGFR1 or the RAF/MEK/ERK pathway.